Ligand Pharma Q2 top-line down 72%

|About: Ligand Pharmaceuticals Inc... (LGND)|By:, SA News Editor

Ligand Pharmaceuticals (LGND) Q2 results: Revenues: $25M (-72.2%); Royalties: $6.6M (-79.0%); Material sales: $8.5M (+11.8%); License fees, milestones and other revenues: $9.8M (-80.8%).

Net Loss: ($14.4M) (-119.7%); Loss Per Share: ($0.74) (-124.7%); Non-GAAP Net Income: $13.9M (-77.1%); Non-GAAP EPS: $0.68 (-73.7%).

2019 guidance: Total Revenues: ~$118M (unch); non-GAAP EPS: ~$3.20 (unch).

Previously: Ligand Pharmaceuticals EPS beats by $0.02, beats on revenue (July 30)

Subscribe for full text news in your inbox